60 Degrees Pharmaceuticals shares are trading higher after the company announced it enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis.

60 Degrees Q2 EPS $(0.90) Misses $(0.86) Estimate, Sales $56.798K Miss $186.000K Estimate

60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.86) by 4.65 percent. This is a 82.04 percent increase over losses of $(5.01) per share from the

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals announced a private placement of 574,713 shares at $1.74 per share, expected to raise approximately $1.0 million in gross proceeds before fees. The offering includes series A and B warrants with exercise prices of $1.49 per share. The company plans to use net proceeds for working capital and general corporate purposes.

60 Degrees Pharmaceuticals Announces $1M Private Placement Of 574,713 Shares At $1.74, Including Warrants